

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-10 (canceled)

Claim 11. (previously presented) A composition for inhibiting endothelial cell proliferation comprising a Kunitz-3 domain fragment of a tissue factor pathway inhibitor, or an active fragment thereof, and a pharmaceutically acceptable carrier.

Claim 12. (previously presented) The composition of Claim 11, wherein the active fragment inhibits cell proliferation.

Claim 13. (canceled)

Claim 14. (previously presented) The composition of Claim 12, wherein the active fragment inhibits angiogenesis.

Claim 15. (previously presented) The composition of Claim 12, wherein the active fragment inhibits angiogenesis-related disease.

Claim 16. (previously presented) The composition of Claim 15, wherein the angiogenesis-related disease is a disease selected from the group consisting of cancer, arthritis, macular degeneration, and diabetic retinopathy.

Claim 17. (previously presented) The composition of Claim 12, wherein the active fragment

Claim 18. (withdrawn) The composition of Claim 12 wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in SEQ ID NO. 2.

Claim 19. (canceled)

Claim 20. (previously presented) The composition of Claim 11, wherein the carrier is a sustained-release matrix.